ClinConnect ClinConnect Logo
Search / Trial NCT01056692

OC000459 Bronchial Allergen Challenge

Launched by OXAGEN LTD · Jan 25, 2010

Trial Information

Current as of July 21, 2025

Completed

Keywords

Asthma Bronchial Allergen Challenge Sputum Eosinophiilia

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Known history of asthma (intermittent wheezing, cough, dyspnoea responsive to inhaled short acting beta agonists).
  • FEV1 \>65% of predicted on at least two occasions at screening.
  • At the screening allergen challenge, a decrease in FEV1 of ≥20% in the early asthmatic reaction and of ≥15% in the LAR to allergen on 3 separate occasions between 3-10hrs post allergen, 2 of which must be consecutive.
  • No steroid usage in the past 12 weeks.
  • Testing positive to skin prick challenge with at least one of the following allergens: house dust mite, pollen or cat hair within the previous 12 months.
  • Non smokers for a minimum of 6 months; less than 10 pack year history.
  • Exclusion Criteria:
  • Respiratory tract pathology other than allergic asthma.
  • Lower respiratory tract infection within 4 weeks prior to an allergen challenge.
  • Receipt of prescribed or OTC medication other than paracetamol or short acting inhaled beta agonists within 14 days of screening or of the first day of each dosing period.

About Oxagen Ltd

Oxagen Ltd. is a biopharmaceutical company dedicated to advancing the development of innovative therapies for unmet medical needs, particularly in the fields of rare and chronic diseases. With a strong focus on precision medicine and genetic research, Oxagen leverages cutting-edge technology and scientific expertise to identify and validate novel drug targets. The company's commitment to rigorous clinical testing and regulatory compliance ensures that its therapeutic candidates are both safe and effective, ultimately aiming to improve patient outcomes and enhance quality of life. Through strategic partnerships and collaborations, Oxagen strives to accelerate the translation of research discoveries into impactful treatments.

Locations

London, , United Kingdom

Manchester, , United Kingdom

Patients applied

0 patients applied

Trial Officials

David Singh, MD

Principal Investigator

Medicines Evaluation Unit, Manchester, UK

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials